187 related articles for article (PubMed ID: 35482320)
1. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.
Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT
Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320
[TBL] [Abstract][Full Text] [Related]
2. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals.
Riveros C; Dechartres A; Perrodeau E; Haneef R; Boutron I; Ravaud P
PLoS Med; 2013 Dec; 10(12):e1001566; discussion e1001566. PubMed ID: 24311990
[TBL] [Abstract][Full Text] [Related]
3. Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: An observational study.
Paladin I; Pranić SM
BMC Med Res Methodol; 2022 Oct; 22(1):262. PubMed ID: 36199040
[TBL] [Abstract][Full Text] [Related]
4. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
Schwartz LM; Woloshin S; Zheng E; Tse T; Zarin DA
Ann Intern Med; 2016 Sep; 165(6):421-30. PubMed ID: 27294570
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.
Pradhan R; Singh S
Drug Saf; 2018 Sep; 41(9):849-857. PubMed ID: 29644579
[TBL] [Abstract][Full Text] [Related]
6. Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.
Shepshelovich D; Goldvaser H; Wang L; Abdul Razak AR; Bedard PL
Invest New Drugs; 2017 Dec; 35(6):827-833. PubMed ID: 28905282
[TBL] [Abstract][Full Text] [Related]
7. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
[TBL] [Abstract][Full Text] [Related]
8. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.
Tang E; Ravaud P; Riveros C; Perrodeau E; Dechartres A
BMC Med; 2015 Aug; 13():189. PubMed ID: 26269118
[TBL] [Abstract][Full Text] [Related]
10. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022.
Xie JS; Kaur H; Tao B; Lee J; Solish D; Kohly R; Margolin E
JAMA Ophthalmol; 2024 Feb; 142(2):123-130. PubMed ID: 38236588
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
12. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
13. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
14. Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study.
Earley A; Lau J; Uhlig K
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23335556
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials on drug-drug interactions registered in ClinicalTrials.gov reported incongruent safety data in published articles: an observational study.
Jurić D; Pranić S; Tokalić R; Milat AM; Mudnić I; Pavličević I; Marušić A
J Clin Epidemiol; 2018 Dec; 104():35-45. PubMed ID: 30081071
[TBL] [Abstract][Full Text] [Related]
16. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
[TBL] [Abstract][Full Text] [Related]
17. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
Swanson MJ; Johnston JL; Ross JS
Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
[TBL] [Abstract][Full Text] [Related]
18. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
Heyward J; Moore TJ; Chen J; Meek K; Lurie P; Alexander GC
Ann Intern Med; 2020 Dec; 173(12):956-963. PubMed ID: 32986486
[TBL] [Abstract][Full Text] [Related]
19. Trial registration, publication rate and characteristics in the research field of otology: A cross-sectional study.
van Heteren JAA; van Beurden I; Peters JPM; Smit AL; Stegeman I
PLoS One; 2019; 14(7):e0219458. PubMed ID: 31291350
[TBL] [Abstract][Full Text] [Related]
20. Data monitoring committees in pediatric randomized controlled trials registered in ClinicalTrials.gov.
Machado T; Mainoli B; Caldeira D; Ferreira JJ; Fernandes RM
Clin Trials; 2023 Dec; 20(6):624-631. PubMed ID: 37366168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
